622 results on '"Nijman, Hans W."'
Search Results
2. Development of [89Zr]Zr-hCD103.Fab01A and [68Ga]Ga-hCD103.Fab01A for PET imaging to noninvasively assess cancer reactive T cell infiltration: Fab-based CD103 immunoPET
3. Automated causal inference in application to randomized controlled clinical trials
4. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
5. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
6. Prognostic benefit of TILs independent of clinicopathological and molecular factors
7. Tumour-infiltrating lymphocytes: from prognosis to treatment selection
8. Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer — a nationwide Dutch cohort study
9. ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors
10. Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands
11. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
12. A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases
13. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
14. Prediction of recurrence risk in endometrial cancer with multimodal deep learning
15. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
16. Automated causal inference in application to randomized controlled clinical trials
17. Strategies to Target Tumor Immunosuppression
18. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy
19. Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer
20. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring
21. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making
22. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial
23. Tumor-infiltrating lymphocytes in the immunotherapy era
24. Treatment of bulky lymph nodes in locally advanced cervical cancer: boosting versus debulking
25. Ovarian cancer
26. Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study
27. Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread — Is lymph node assessment only required in patients with LVSI?
28. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.
29. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials
30. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
31. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
32. Borderline tumours of the ovary: Common practice in the Netherlands
33. Strategies to Target Tumor Immunosuppression
34. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
35. ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.
36. Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
37. Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery
38. Development of 89Zr and 68Ga-anti-CD103 Fab-fragments for PET imaging to non-invasively assess cancer reactive T cell infiltration--- Fab-based CD103 immunoPET
39. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides
40. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
41. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
42. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
43. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
44. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
45. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
46. Supplementary Methods from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer
47. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
48. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
49. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
50. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.